AFX N Stock Overview
Operates as a medical technology company in Germany, rest of Europe, North America, and Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Carl Zeiss Meditec AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3,258.20 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.83 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -27.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| AFX N | MX Medical Equipment | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | 0% | 0% | 0% |
Return vs Industry: AFX N exceeded the MX Medical Equipment industry which returned -2.1% over the past year.
Return vs Market: AFX N underperformed the MX Market which returned 3.7% over the past year.
Price Volatility
| AFX N volatility | |
|---|---|
| AFX N Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: AFX N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AFX N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1846 | 4,624 | Markus Weber | www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir |
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers offers products and solutions for the diagnosis and treatment of chronic eye diseases; and systems and consumables for refractive surgery.
Carl Zeiss Meditec AG Fundamentals Summary
| AFX N fundamental statistics | |
|---|---|
| Market cap | Mex$183.06b |
| Earnings (TTM) | Mex$5.17b |
| Revenue (TTM) | Mex$37.59b |
35.4x
P/E Ratio4.9x
P/S RatioIs AFX N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AFX N income statement (TTM) | |
|---|---|
| Revenue | €2.02b |
| Cost of Revenue | €846.14m |
| Gross Profit | €1.18b |
| Other Expenses | €897.48m |
| Earnings | €278.29m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Aug 04, 2023
| Earnings per share (EPS) | 3.11 |
| Gross Margin | 58.15% |
| Net Profit Margin | 13.76% |
| Debt/Equity Ratio | 0% |
How did AFX N perform over the long term?
See historical performance and comparison